Arlo-Cel Shows Promise in Treating Relapsed Myeloma Patients
A new targeted CAR T-cell therapy, arlocabtagene autoleucel (arlo-cel), has demonstrated impressive efficacy and safety for patients with relapsed or refractory multiple myeloma. Research presented at the 22nd Annual International…